Novartis Institutes for BioMedical Research, Global Discovery Chemistry, Cambridge, Massachusetts 02139, USA.
Proteins. 2010 Sep;78(12):2571-86. doi: 10.1002/prot.22767.
LDL cholesterol (LDL-C) is cleared from plasma via cellular uptake and internalization processes that are largely mediated by the low-density lipoprotein cholesterol receptor (LDL-R). LDL-R is targeted for lysosomal degradation by association with proprotein convertase subtilisin-kexin type 9 (PCSK9). Gain of function mutations in PCSK9 can result in excessive loss of receptors and dyslipidemia. On the other hand, receptor-sparing phenomena, including loss-of-function mutations or inhibition of PCSK9, can lead to enhanced clearance of plasma lipids. We hypothesize that desolvation and resolvation processes, in many cases, constitute rate-determining steps for protein-ligand association and dissociation, respectively. To test this hypothesis, we analyzed and compared the predicted desolvation properties of wild-type versus gain-of-function mutant Asp374Tyr PCSK9 using WaterMap, a new in silico method for predicting the preferred locations and thermodynamic properties of water solvating proteins ("hydration sites"). We compared these results with binding kinetics data for PCSK9, full-length LDL-R ectodomain, and isolated EGF-A repeat. We propose that the fast k(on) and entropically driven thermodynamics observed for PCSK9-EGF-A binding stem from the functional replacement of water occupying stable PCSK9 hydration sites (i.e., exchange of PCSK9 H-bonds from water to polar EGF-A groups). We further propose that the relatively fast k(off) observed for EGF-A unbinding stems from the limited displacement of solvent occupying unstable hydration sites. Conversely, the slower k(off) observed for EGF-A and LDL-R unbinding from Asp374Tyr PCSK9 stems from the destabilizing effects of this mutation on PCSK9 hydration sites, with a concomitant increase in the persistence of the bound complex.
低密度脂蛋白胆固醇(LDL-C)通过细胞摄取和内化过程从血浆中清除,这些过程主要由低密度脂蛋白胆固醇受体(LDL-R)介导。LDL-R 通过与脯氨酸内切酶枯草杆菌蛋白酶/ kexin 9 型(PCSK9)结合而被靶向溶酶体降解。PCSK9 的获得性功能突变可导致受体过度丢失和血脂异常。另一方面,受体保存现象,包括功能丧失突变或 PCSK9 抑制,可导致血浆脂质的清除增强。我们假设,在许多情况下,去溶剂化和再溶剂化过程分别构成蛋白质-配体结合和解离的速率决定步骤。为了验证这一假设,我们使用 WaterMap 分析和比较了野生型与获得性功能突变 Asp374Tyr PCSK9 的预测去溶剂化特性,WaterMap 是一种新的用于预测蛋白质水合位置和热力学性质的计算方法(“水合位点”)。我们将这些结果与 PCSK9、全长 LDL-R 胞外域和分离的 EGF-A 重复的结合动力学数据进行了比较。我们提出,PCSK9-EGF-A 结合观察到的快速 k(on)和熵驱动热力学源于稳定 PCSK9 水合位点上占据的功能替代(即,PCSK9 氢键从水中交换到极性 EGF-A 基团)。我们进一步提出,EGF-A 解吸观察到的相对较快的 k(off)源于占据不稳定水合位点的溶剂的有限位移。相反,Asp374Tyr PCSK9 上观察到的 EGF-A 和 LDL-R 解吸较慢,这是由于该突变对 PCSK9 水合位点的破坏作用,导致结合复合物的持续时间延长。